Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Second interim analysis (IA2) of MAGNITUDE Meeting Abstract
| Authors: | Efstathiou, E.; Smith, M. R.; Sandhu, S.; Attard, G.; Saad, M.; Olmos, D.; Castro, E.; Roubaud, G.; Gomes, A. J.; Small, E. J.; Rathkopf, D. E.; Gurney, H.; Jung, W.; Mason, G.; Francis, P. S. J.; Wang, G. C.; Wu, D.; Diorio, B.; Lopez- Gitlitz, A. M.; Chi, K. N. |
| Abstract Title: | Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Second interim analysis (IA2) of MAGNITUDE |
| Meeting Title: | 2023 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2023 Feb 16-18 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-02-20 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.6_suppl.170 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting abstract: 170 -- Accession Number: 162006437 -- Entry Date: In Process -- Revision Date: 20230223 -- Publication Type: Article -- Supplement Title: 2/21/2023 Supplement -- Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 8309333. -- Source: Cinahl |
